Safety-Related Labeling Changes
Electrolyte Abnormalities, Elevated liver enzymes, Gastrointestinal disorders, Fatigue, dysgeusia, musculoskeletal pain, increased creatinine, decreased albumin, and decreased hemoglobin
Trade Name
Balversa
Updated Section
4.8 Undesirable effects
Month
Apr,2023